{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:18:33Z","timestamp":1768317513091,"version":"3.49.0"},"reference-count":266,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.intimp.2022.108791","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T06:40:50Z","timestamp":1650955250000},"page":"108791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["A century of attempts to develop an effective tuberculosis vaccine: Why they failed?"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8416-3792","authenticated-orcid":false,"given":"Saman","family":"Soleimanpour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atieh","family":"Yaghoubi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fereshteh","family":"Sadat Seddighinia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.A. Rahim","family":"Rezaee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.108791_b0005","unstructured":"(WHO) WHO. Global tuberculosis report 2019, 2019."},{"key":"10.1016\/j.intimp.2022.108791_b0010","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/S0140-6736(10)60410-2","article-title":"Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis","volume":"375","author":"Gandhi","year":"2010","journal-title":"Lancet (London, England)."},{"issue":"Suppl 3","key":"10.1016\/j.intimp.2022.108791_b0015","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1086\/651491","article-title":"Extensively drug-resistant tuberculosis: there must be some kind of way out of here","volume":"50","author":"Cegielski","year":"2010","journal-title":"Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am."},{"issue":"4","key":"10.1016\/j.intimp.2022.108791_b0020","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/joim.12264","article-title":"Totally drug-resistant tuberculosis and adjunct therapies","volume":"277","author":"Parida","year":"2015","journal-title":"J. Int. Med."},{"issue":"9514","key":"10.1016\/j.intimp.2022.108791_b0025","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0140-6736(06)68392-X","article-title":"WHO's new stop TB strategy","volume":"367","author":"Raviglione","year":"2006","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.intimp.2022.108791_b0030","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1473-3099(11)70146-3","article-title":"Fact and fiction in tuberculosis vaccine research: 10 years later","volume":"11","author":"Kaufmann","year":"2011","journal-title":"Lancet Infect. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2022.108791_b0035","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.immuni.2010.06.003","article-title":"Discrete roles of STAT4 and STAT6 transcription factors in tuning epigenetic modifications and transcription during T helper cell differentiation","volume":"32","author":"Wei","year":"2010","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.intimp.2022.108791_b0040","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.immuni.2012.09.007","article-title":"The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses","volume":"37","author":"Zhu","year":"2012","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.intimp.2022.108791_b0045","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4049\/jimmunol.136.7.2348","article-title":"Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins","volume":"136","author":"Mosmann","year":"1986","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2022.108791_b0050","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2022.108791_b0055","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells","volume":"361","author":"Miossec","year":"2009","journal-title":"New England J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.14712\/18059694.2016.63","article-title":"Regulatory T cells (TREG) and their roles in immune system with respect to immunopathological disorders","volume":"53","author":"Kondelkova","year":"2010","journal-title":"Acta Medica (Hradec Kralove)"},{"issue":"5","key":"10.1016\/j.intimp.2022.108791_b0065","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI31202","article-title":"Tregs and rethinking cancer immunotherapy","volume":"117","author":"Curiel","year":"2007","journal-title":"J. Clini. Investig."},{"key":"10.1016\/j.intimp.2022.108791_b0070","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/854507","article-title":"Th1 and Th17 cells in tuberculosis: protection, pathology, and biomarkers","volume":"2015","author":"Lyadova","year":"2015","journal-title":"Mediat. Inflamm."},{"issue":"4\u20135","key":"10.1016\/j.intimp.2022.108791_b0075","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.imbio.2017.11.001","article-title":"Macrophages: their role, activation and polarization in pulmonary diseases","volume":"223","author":"Arora","year":"2018","journal-title":"Immunobiology"},{"key":"10.1016\/j.intimp.2022.108791_b0080","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-physiol-022516-034339","article-title":"Macrophage polarization","volume":"79","author":"Murray","year":"2017","journal-title":"Ann. Rev. Physiol."},{"key":"10.1016\/j.intimp.2022.108791_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2017.09.002","article-title":"Macrophage polarization and allergic asthma","volume":"191","author":"Saradna","year":"2018","journal-title":"Trans. Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-017-0522-0","article-title":"Dual polarization of human alveolar macrophages progressively increases with smoking and COPD severity","volume":"18","author":"Bazzan","year":"2017","journal-title":"Respirat. Res."},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b0095","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3390\/ijms19020582","article-title":"Lung macrophage phenotypes and functional responses: role in the pathogenesis of COPD","volume":"19","author":"Yamasaki","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2022.108791_b0100","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/ijms17030131","article-title":"Mycobacterium tuberculosis: manipulator of protective immunity","volume":"17","author":"Korb","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2022.108791_b0105","first-page":"6","article-title":"Understanding the immune response to M. tuberculosis","volume":"8","author":"Urdahl","year":"2015","journal-title":"Nat. Educ."},{"issue":"3","key":"10.1016\/j.intimp.2022.108791_b0110","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1399-0039.2009.01301.x","article-title":"Evasion and subversion of antigen presentation by Mycobacterium tuberculosis","volume":"74","author":"Baena","year":"2009","journal-title":"Tissue Antigens"},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b0115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.clim.2005.01.012","article-title":"Armed CD4+ Th1 effector cells and activated macrophages participate in bile duct injury in murine biliary atresia","volume":"115","author":"Cara","year":"2005","journal-title":"Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108791_b0120","doi-asserted-by":"crossref","first-page":"e0121070","DOI":"10.1371\/journal.pone.0121070","article-title":"IL-4Ralpha-dependent alternative activation of macrophages is not decisive for Mycobacterium tuberculosis pathology and bacterial burden in mice","volume":"10","author":"Guler","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2022.108791_b0125","doi-asserted-by":"crossref","unstructured":"N.A. Zondervan, J.C.J. van Dam, P.J. Schaap, Regulation of Three Virulence Strategies of Mycobacterium tuberculosis: A Success Story. 2018;19(2).","DOI":"10.3390\/ijms19020347"},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00281-015-0537-x","article-title":"Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review","volume":"38","author":"Kiran","year":"2016","journal-title":"Semin. Immunopathol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b0135","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/imr.12252","article-title":"Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses","volume":"264","author":"Lenaerts","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2022.108791_b0140","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1600-065X.2008.00702.x","article-title":"The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis","volume":"226","author":"Cooper","year":"2008","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2022.108791_b0145","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.4049\/jimmunol.1500981","article-title":"Role of B cells in mucosal vaccine-induced protective CD8+T cell immunity against pulmonary tuberculosis","volume":"195","author":"Amandeep","year":"2015","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2022.108791_b0150","first-page":"1179","article-title":"Latent Mycobacterium tuberculosis Infection","volume":"373","author":"Getahun","year":"2015","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.108791_b0155","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3389\/fimmu.2017.00084","article-title":"Mycobacterial dormancy systems and host responses in tuberculosis","volume":"8","author":"Peddireddy","year":"2017","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2022.108791_b0160","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/jama.2016.11021","article-title":"The challenge of latent TB infection","volume":"316","author":"Blumberg","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2022.108791_b0165","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fcimb.2016.00124","article-title":"Genetic-and-epigenetic interspecies networks for cross-talk mechanisms in human macrophages and dendritic cells during MTB infection","volume":"6","author":"Li","year":"2016","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"5","key":"10.1016\/j.intimp.2022.108791_b0170","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.tim.2012.03.002","article-title":"Can the battle against tuberculosis gain from epigenetic research?","volume":"20","author":"Esterhuyse","year":"2012","journal-title":"Trends Microbiol."},{"issue":"4","key":"10.1016\/j.intimp.2022.108791_b0175","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2217\/epi.16.1","article-title":"The role of epigenetics in tuberculosis infection","volume":"8","author":"Kathirvel","year":"2016","journal-title":"Epigenomics"},{"key":"10.1016\/j.intimp.2022.108791_b0180","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev-immunol-032712-100019","article-title":"T cell-mediated host immune defenses in the lung","volume":"31","author":"Chen","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b0185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nri2487","article-title":"Epigenetic control of T-helper-cell differentiation","volume":"9","author":"Wilson","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2022.108791_b0190","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/ni0703-616","article-title":"An epigenetic view of helper T cell differentiation","volume":"4","author":"Mark Ansel","year":"2003","journal-title":"Nat. Immunol."},{"issue":"26","key":"10.1016\/j.intimp.2022.108791_b0195","doi-asserted-by":"crossref","first-page":"15137","DOI":"10.1073\/pnas.261570598","article-title":"T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells","volume":"98","author":"Lighvani","year":"2001","journal-title":"PNAS"},{"issue":"5523","key":"10.1016\/j.intimp.2022.108791_b0200","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1126\/science.1059835","article-title":"Role of T-bet in commitment of TH1 cells before IL-12-dependent selection","volume":"292","author":"Mullen","year":"2001","journal-title":"Science (New York, NY)."},{"issue":"24","key":"10.1016\/j.intimp.2022.108791_b0205","doi-asserted-by":"crossref","first-page":"10467","DOI":"10.1007\/s00253-015-6952-z","article-title":"APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice","volume":"99","author":"Soleimanpour","year":"2015","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.intimp.2022.108791_b0210","first-page":"6","article-title":"The memory immune response to tuberculosis Microbiol","volume":"4","author":"Kirman","year":"2016","journal-title":"Spectrum."},{"issue":"3","key":"10.1016\/j.intimp.2022.108791_b0215","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.immuni.2007.07.022","article-title":"T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis","volume":"27","author":"Harris","year":"2007","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2022.108791_b0220","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/07388551.2016.1163323","article-title":"Fcgamma1 fragment of IgG1 as a powerful affinity tag in recombinant Fc-fusion proteins: immunological, biochemical and therapeutic properties","volume":"37","author":"Soleimanpour","year":"2017","journal-title":"Crit. Rev. Biotechnol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108791_b0225","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4049\/jimmunol.177.3.1416","article-title":"Cutting edge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection","volume":"177","author":"Cruz","year":"2006","journal-title":"J. Immunol. (Baltimore, Md : 1950)"},{"issue":"6","key":"10.1016\/j.intimp.2022.108791_b0230","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.cytogfr.2010.10.004","article-title":"IL-17 and Th17 cells in tuberculosis","volume":"21","author":"Torrado","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.intimp.2022.108791_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/854507","article-title":"Th1 and Th17 cells in tuberculosis: protection, pathology, and biomarkers","volume":"2015","author":"Lyadova","year":"2015","journal-title":"Mediat. Inflamm."},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b0240","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1128\/IAI.68.2.577-583.2000","article-title":"Neutrophils play a protective nonphagocytic role in systemic Mycobacterium tuberculosis infection of mice","volume":"68","author":"Pedrosa","year":"2000","journal-title":"Infect. Immun."},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b0245","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14760584.2018.1406309","article-title":"Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost?","volume":"17","author":"Khademi","year":"2018","journal-title":"Expert Rev. Vaccines"},{"issue":"5","key":"10.1016\/j.intimp.2022.108791_b0250","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1084\/jem.183.5.2391","article-title":"Interferon gamma production by natural killer (NK) cells and NK1. 1+ T cells upon NKR-P1 cross-linking","volume":"183","author":"Arase","year":"1996","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b0255","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1084\/jem.178.2.567","article-title":"Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice","volume":"178","author":"Scharton","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2022.108791_b0260","article-title":"Immune response to Mycobacterium tuberculosis: a narrative review","volume":"350","author":"De Martino","year":"2019","journal-title":"Front. Pediatr."},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b0265","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/imr.12217","article-title":"Beyond macrophages: the diversity of mononuclear cells in tuberculosis","volume":"262","author":"Srivastava","year":"2014","journal-title":"Immunol. Rev."},{"issue":"8","key":"10.1016\/j.intimp.2022.108791_b0270","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/eji.201545493","article-title":"Versatile myeloid cell subsets contribute to tuberculosis-associated inflammation","volume":"45","author":"Dorhoi","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2022.108791_b0275","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tube.2018.10.007","article-title":"A subset of CD1c+ dendritic cells is increased in patients with tuberculosis and promotes Th17 cell polarization","volume":"113","author":"Liu","year":"2018","journal-title":"Tuberculosis"},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b0280","first-page":"53","article-title":"History of BCG Vaccine","volume":"8","author":"Luca","year":"2013","journal-title":"Maedica"},{"key":"10.1016\/j.intimp.2022.108791_b0285","first-page":"g4643","article-title":"Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis","volume":"349","author":"Roy","year":"2014","journal-title":"BMJ (Clin. Res. ed)."},{"key":"10.1016\/j.intimp.2022.108791_b0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/193923","article-title":"Cellular and humoral mechanisms involved in the control of tuberculosis","author":"Joaquin Zu\u00f1iga","year":"2012","journal-title":"Clin. Dev. Immunol."},{"issue":"21","key":"10.1016\/j.intimp.2022.108791_b0295","first-page":"193","article-title":"vaccination guidelines for infants at risk for HIV infection","volume":"82","author":"Revised","year":"2007","journal-title":"Releve epidemiologique hebdomadaire."},{"key":"10.1016\/j.intimp.2022.108791_b0300","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.job.2012.04.002","article-title":"Current status of tuberculosis and recombinant bacillus Calmette-Gu\u00e9rin vaccines","volume":"54","author":"Ohara","year":"2012","journal-title":"J. Oral Biosci."},{"key":"10.1016\/j.intimp.2022.108791_b0305","doi-asserted-by":"crossref","first-page":"e30180","DOI":"10.5812\/pedinfect.30180","article-title":"BCG vaccination as a prevention strategy, threats and benefits","volume":"4","author":"Shirvani","year":"2016","journal-title":"Arch. Pediatr. Infect. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b0310","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.vaccine.2006.07.020","article-title":"The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children","volume":"25","author":"Hesseling","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b0315","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1742-4933-10-25","article-title":"Reactivation of immune responses against Mycobacterium tuberculosis by boosting with the CpG oligomer in aged mice primarily vaccinated with Mycobacterium bovis BCG","volume":"10","author":"Taniguchi","year":"2013","journal-title":"Immun. Ageing: I & A."},{"issue":"9","key":"10.1016\/j.intimp.2022.108791_b0320","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.tim.2012.06.002","article-title":"New pathways of protective and pathological host defense to mycobacteria","volume":"20","author":"Ottenhoff","year":"2012","journal-title":"Trends Microbiol."},{"issue":"35","key":"10.1016\/j.intimp.2022.108791_b0325","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1016\/j.vaccine.2009.05.021","article-title":"The potential impact of helminth infection on trials of novel tuberculosis vaccines","volume":"27","author":"Hatherill","year":"2009","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.intimp.2022.108791_b0330","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1586\/14787210.5.3.475","article-title":"Chronic helminth infections may negatively influence immunity against tuberculosis and other diseases of public health importance","volume":"5","author":"Elias","year":"2007","journal-title":"Expert Rev. Anti-infective Therapy"},{"issue":"4","key":"10.1016\/j.intimp.2022.108791_b0335","first-page":"209","article-title":"Toward novel vaccines against tuberculosis: current hopes and obstacles","volume":"83","author":"Thaiss","year":"2010","journal-title":"Yale J. Biol. Med."},{"issue":"6","key":"10.1016\/j.intimp.2022.108791_b0340","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.tube.2009.09.004","article-title":"Ultraviolet radiation reduces resistance to Mycobacterium tuberculosis infection in BCG-vaccinated guinea pigs","volume":"89","author":"Jeevan","year":"2009","journal-title":"Tuberculosis (Edinburgh, Scotland)."},{"issue":"Suppl 2","key":"10.1016\/j.intimp.2022.108791_b0345","doi-asserted-by":"crossref","first-page":"B223","DOI":"10.1016\/j.vaccine.2012.11.081","article-title":"Preventive vaccines for tuberculosis","volume":"31","author":"Evans","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.intimp.2022.108791_b0350","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018523","article-title":"Novel vaccination strategies against tuberculosis","volume":"4","author":"Andersen","year":"2014","journal-title":"Cold Spring Harbor Perspect. Med."},{"issue":"9","key":"10.1016\/j.intimp.2022.108791_b0355","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.vaccine.2012.12.053","article-title":"Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial","volume":"31","author":"Grode","year":"2013","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.intimp.2022.108791_b0360","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1172\/JCI24617","article-title":"Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin","volume":"115","author":"Grode","year":"2005","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.intimp.2022.108791_b0365","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3389\/fimmu.2017.01147","article-title":"The recombinant Bacille Calmette-Gu\u00e9rin vaccine VPM1002: ready for clinical efficacy testing","volume":"8","author":"Nieuwenhuizen","year":"2017","journal-title":"Front. Immunol."},{"issue":"52","key":"10.1016\/j.intimp.2022.108791_b0370","doi-asserted-by":"crossref","first-page":"7608","DOI":"10.1016\/j.vaccine.2012.10.031","article-title":"The recombinant tuberculosis vaccine rBCG DeltaureC::hly(+) induces apoptotic vesicles for improved priming of CD4(+) and CD8(+) T cells","volume":"30","author":"Farinacci","year":"2012","journal-title":"Vaccine"},{"issue":"5493","key":"10.1016\/j.intimp.2022.108791_b0375","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1126\/science.290.5493.992","article-title":"A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity","volume":"290","author":"Decatur","year":"2000","journal-title":"Science (New York, NY)."},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b0380","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1742-4658.2011.08405.x","article-title":"pH dependence of listeriolysin O aggregation and pore-forming ability","volume":"279","author":"Bavdek","year":"2012","journal-title":"FEBS J."},{"issue":"10","key":"10.1016\/j.intimp.2022.108791_b0385","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/infdis\/jir592","article-title":"Recombinant BCG \u0394ureC hly+ Induces Superior Protection Over Parental BCG by Stimulating a Balanced Combination of Type 1 and Type 17 Cytokine Responses","volume":"204","author":"Desel","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.108791_b0390","unstructured":"GmbH VPM. Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa. ClinicalTrialsgov. 2013;NCT01479972."},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b0395","doi-asserted-by":"crossref","first-page":"e00439","DOI":"10.1128\/CVI.00439-16","article-title":"Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa","volume":"24","author":"Loxton","year":"2017","journal-title":"Clin. Vacc. Immunol.: CVI."},{"key":"10.1016\/j.intimp.2022.108791_b0400","unstructured":"NCT03152903 CgI. Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence in India. Serum Institute of India Pvt Ltd. 2017."},{"issue":"11","key":"10.1016\/j.intimp.2022.108791_b0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078966","article-title":"The Tuberculosis Vaccine Candidate Bacillus CalmetteGuerin DureC::hly Coexpressing Human Interleukin-7 or -18 Enhances Antigen-Specific T Cell Responses in Mice","volume":"8","author":"Rao","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.intimp.2022.108791_b0410","unstructured":"D.A. Cuzzone, R.P. Kataru, G.E. Hespe, J.S. Torrisi, J.J. Huang, J.C. Gardenier, et al. Nature communications."},{"issue":"25","key":"10.1016\/j.intimp.2022.108791_b0415","doi-asserted-by":"crossref","first-page":"13853","DOI":"10.1073\/pnas.250480397","article-title":"Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model","volume":"97","author":"Horwitz","year":"2000","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2022.108791_b0420","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fcimb.2016.00003","article-title":"Evaluation of Immunogenicity and Protective Efficacy Elicited by Mycobacterium bovis BCG Overexpressing Ag85A Protein against Mycobacterium tuberculosis Aerosol Infection","volume":"6","author":"Xu","year":"2016","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"4","key":"10.1016\/j.intimp.2022.108791_b0425","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1128\/IAI.71.4.1672-1679.2003","article-title":"A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis","volume":"71","author":"Horwitz","year":"2003","journal-title":"Infect. Immun."},{"issue":"10","key":"10.1016\/j.intimp.2022.108791_b0430","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1086\/592450","article-title":"A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers","volume":"198","author":"Hoft","year":"2008","journal-title":"J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.intimp.2022.108791_b0435","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1128\/IAI.01499-13","article-title":"rBCG30-induced immunity and cross-protection against Mycobacterium leprae challenge are enhanced by boosting with the Mycobacterium tuberculosis 30-kilodalton antigen 85B","volume":"82","author":"Gillis","year":"2014","journal-title":"Infect. Immun."},{"key":"10.1016\/j.intimp.2022.108791_b0440","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ebiom.2016.04.010","article-title":"Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naive Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial","volume":"7","author":"Hoft","year":"2016","journal-title":"EBioMedicine"},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2022.108791_b0445","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1471-2334-14-S1-S2","article-title":"Vaccine against tuberculosis: what's new?","volume":"14","author":"Montagnani","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.intimp.2022.108791_b0450","unstructured":"NCT03026972 CgI. A Phase \u2160Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC\/BCO2). Anhui Zhifei Longcom Biologic Pharmacy Co, Ltd. 2017."},{"issue":"42","key":"10.1016\/j.intimp.2022.108791_b0455","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1016\/j.vaccine.2013.07.051","article-title":"Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials","volume":"31","author":"Arbues","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b0460","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/eji.201141903","article-title":"Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4+ T-cell memory","volume":"42","author":"Nambiar","year":"2012","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b0465","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.chom.2008.01.002","article-title":"Mutation in the transcriptional regulator PhoP contributes to avirulence of Mycobacterium tuberculosis H37Ra strain","volume":"3","author":"Lee","year":"2008","journal-title":"Cell Host Microbe."},{"issue":"4","key":"10.1016\/j.intimp.2022.108791_b0470","doi-asserted-by":"crossref","first-page":"e5264","DOI":"10.1371\/journal.pone.0005264","article-title":"MVA 85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques","volume":"4","author":"Frank","year":"2009","journal-title":"PloS One"},{"key":"10.1016\/j.intimp.2022.108791_b0475","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tube.2015.10.010","article-title":"MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice","volume":"96","author":"Aguilo","year":"2016","journal-title":"Tuberculosis (Edinburgh, Scotland)."},{"issue":"9","key":"10.1016\/j.intimp.2022.108791_b0480","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S2213-2600(19)30251-6","article-title":"Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial","volume":"7","author":"Tameris","year":"2019","journal-title":"Lancet Respirat. Med."},{"key":"10.1016\/j.intimp.2022.108791_b0485","unstructured":"NCT04152161 CgI. BCG Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection. Bill & Melinda Gates Medical Research Institute. 2019."},{"issue":"8","key":"10.1016\/j.intimp.2022.108791_b0490","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1586\/14760584.2016.1170599","article-title":"Why don't we have an effective tuberculosis vaccine yet?","volume":"15","author":"Davenne","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.intimp.2022.108791_b0495","unstructured":"(WHO) WHO. Global tuberculosis reports 2016. WHO. 2016."},{"issue":"4","key":"10.1016\/j.intimp.2022.108791_b0500","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1164\/rccm.201208-1385OC","article-title":"Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72\/AS01 in South African adults","volume":"188","author":"Day","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"17","key":"10.1016\/j.intimp.2022.108791_b0505","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.vaccine.2012.05.035","article-title":"Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72\/AS01 as compared to the M72\/AS02 and Mtb72F\/AS02 tuberculosis candidate vaccine formulations: a randomized trial","volume":"31","author":"Leroux-Roels","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2022.108791_b0510","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fimmu.2018.00564","article-title":"Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72\/AS01 in Bacillus Calmette\u2013Gu\u00e9rin-Vaccinated Adults","volume":"9","author":"van den Berg","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b0515","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tube.2012.10.011","article-title":"The candidate tuberculosis vaccine Mtb72F\/AS02 in PPD positive adults: a randomized controlled phase I\/II study","volume":"93","author":"Spertini","year":"2013","journal-title":"Tuberculosis (Edinburgh, Scotland)."},{"key":"10.1016\/j.intimp.2022.108791_b0520","doi-asserted-by":"crossref","unstructured":"O. Van Der Meeren, M. Hatherill, V. Nduba, R.J. Wilkinson, M. Muyoyeta, E. Van Brakel, et al., Phase 2b placebo-controlled trial of M72\/AS01(E) candidate vaccine to prevent active tuberculosis in adults, New Engl. J. Med. (2018) doi:10.1056\/NEJMoa1803484.","DOI":"10.1056\/NEJMoa1803484"},{"key":"10.1016\/j.intimp.2022.108791_b0525","article-title":"Clinical Development of New TB Vaccines: Recent Advances and Next Steps","author":"Hatherill","year":"2020103154","journal-title":"Front Microbiol."},{"issue":"4","key":"10.1016\/j.intimp.2022.108791_b0530","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3390\/vaccines7040166","article-title":"First-In-Human Trials of GamTBvac, a Recombinant Subunit Tuberculosis Vaccine Candidate: Safety and Immunogenicity Assessment","volume":"7","author":"Vasina","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.intimp.2022.108791_b0535","doi-asserted-by":"crossref","unstructured":"A.P. Tkachuk, V.A. Gushchin, Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models 12(4) (2017) e0176784.","DOI":"10.1371\/journal.pone.0176784"},{"key":"10.1016\/j.intimp.2022.108791_b0540","unstructured":"NCT03878004 CgI. Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac. Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation. 2019."},{"issue":"20","key":"10.1016\/j.intimp.2022.108791_b0545","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1016\/j.vaccine.2010.02.094","article-title":"Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers","volume":"28","author":"van Dissel","year":"2010","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.intimp.2022.108791_b0550","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1128\/IAI.72.10.6148-6150.2004","article-title":"Protective Effect of a Tuberculosis Subunit Vaccine Based on a Fusion of Antigen 85B and ESAT-6 in the Aerosol Guinea Pig Model","volume":"72","author":"Olsen","year":"2004","journal-title":"Infect. Immun."},{"issue":"11","key":"10.1016\/j.intimp.2022.108791_b0555","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.vaccine.2010.12.135","article-title":"Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection","volume":"29","author":"van Dissel","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b0560","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.vaccine.2016.11.023","article-title":"H1:IC31 vaccination is safe and induces long-lived TNF-alpha(+)IL-2(+)CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: a randomized trial","volume":"35","author":"Mearns","year":"2017","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.intimp.2022.108791_b0565","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.vaccine.2009.10.114","article-title":"Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen","volume":"28","author":"Skeiky","year":"2010","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.intimp.2022.108791_b0570","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.vaccine.2017.01.055","article-title":"Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials","volume":"35","author":"Norrby","year":"2017","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.intimp.2022.108791_b0575","doi-asserted-by":"crossref","first-page":"e39909","DOI":"10.1371\/journal.pone.0039909","article-title":"The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity","volume":"7","author":"Billeskov","year":"2012","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.intimp.2022.108791_b0580","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.4049\/jimmunol.174.10.6332","article-title":"Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy","volume":"174","author":"Dietrich","year":"2005","journal-title":"J. Immunol. (Baltimore, Md : 1950)"},{"key":"10.1016\/j.intimp.2022.108791_b0585","doi-asserted-by":"crossref","unstructured":"Mike Frick El, lindsay McKenna. The pipeline 2016, in: edition T, editor. i-base\/Treatment Action Group; 2016. p. 143.","DOI":"10.1201\/b19603-11"},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b0590","doi-asserted-by":"crossref","first-page":"e1502","DOI":"10.1371\/journal.pone.0001502","article-title":"The enduring hypoxic response of Mycobacterium tuberculosis","volume":"3","author":"Rustad","year":"2008","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.intimp.2022.108791_b0595","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/joim.12212","article-title":"Recent advances towards tuberculosis control: vaccines and biomarkers","volume":"275","author":"Weiner","year":"2014","journal-title":"J. Int. Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b0600","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jmhi.2013.04.002","article-title":"A novel approach to eradicate latent TB: Based on resuscitation promoting factors","volume":"7","author":"Seidi","year":"2013","journal-title":"J. Med. Hypotheses Ideas"},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b0605","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.micinf.2011.08.011","article-title":"Potential of Mycobacterium tuberculosis resuscitation-promoting factors as antigens in novel tuberculosis sub-unit vaccines","volume":"14","author":"Romano","year":"2012","journal-title":"Microbes Infect."},{"issue":"4","key":"10.1016\/j.intimp.2022.108791_b0610","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1080\/21645515.2015.1120393","article-title":"Current status of new tuberculosis vaccine in children","volume":"12","author":"Pang","year":"2016","journal-title":"Hum. Vaccines Immunotherap."},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b0615","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm.2285","article-title":"A multistage tuberculosis vaccine that confers efficient protection before and after exposure","volume":"17","author":"Aagaard","year":"2011","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.intimp.2022.108791_b0620","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/cid\/cix834","article-title":"Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial","volume":"66","author":"Nemes","year":"2018","journal-title":"Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.intimp.2022.108791_b0625","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1186\/s12879-016-1938-8","article-title":"The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection","volume":"16","author":"Tonby","year":"2016","journal-title":"BMC Infect. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b0630","first-page":"20","article-title":"Increased protection and decreased lung immunopathology induced by the ID93\/GLA-SE vaccine candidate following infection with Mycobacterium tuberculosis HN878","volume":"196","author":"Baldwin","year":"2016","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2022.108791_b0635","first-page":"34","article-title":"and The TBVPX-113 Study Team. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial","volume":"3","author":"Rhea","year":"2018","journal-title":"NPJ Vaccines"},{"issue":"5","key":"10.1016\/j.intimp.2022.108791_b0640","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.4049\/jimmunol.1102696","article-title":"The importance of adjuvant formulation in the development of a tuberculosis vaccine","volume":"188","author":"Baldwin","year":"2012","journal-title":"J. Immunol. (Baltimore, Md: 1950)"},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b0645","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/CVI.00458-15","article-title":"Protection and Long-Lived Immunity Induced by the ID93\/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate","volume":"23","author":"Baldwin","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.intimp.2022.108791_b0650","unstructured":"NCT01599897 CgI. Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers, 2012. [http:\/\/clinicaltrialsgov\/ct2\/show\/NCT01599897?term=id93+gla&rank=1]."},{"key":"10.1016\/j.intimp.2022.108791_b0655","unstructured":"NCT01927159 CgI. Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers; 2013. [http:\/\/clinicaltrialsgov\/ct2\/show\/NCT01927159?term=id93+gla&rank=2]."},{"key":"10.1016\/j.intimp.2022.108791_b0660","unstructured":"NCT02465216 CgI. Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion, 2015. [https:\/\/clinicaltrialsgov\/ct2\/show\/NCT02465216]."},{"issue":"3","key":"10.1016\/j.intimp.2022.108791_b0665","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/2051013615593891","article-title":"Recent advances in the development of vaccines for tuberculosis","volume":"3","author":"Ahsan","year":"2015","journal-title":"Ther. Adv. Vaccines"},{"issue":"4","key":"10.1016\/j.intimp.2022.108791_b0670","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-2600(18)30077-8","article-title":"Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial","volume":"6","author":"Penn-Nicholson","year":"2018","journal-title":"Lancet Respirat. Med."},{"key":"10.1016\/j.intimp.2022.108791_b0675","unstructured":"NCT03806686 CgI. Phase 2a Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers. Quratis Inc. 2019."},{"key":"10.1016\/j.intimp.2022.108791_b0680","unstructured":"Work V. Understanding and Explaining Viral Vector COVID-19 Vaccines."},{"key":"10.1016\/j.intimp.2022.108791_b0685","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector-based vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2022.108791_b0690","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tube.2004.09.015","article-title":"Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials","volume":"85","author":"McShane","year":"2005","journal-title":"Tuberculosis (Edinburgh, Scotland)."},{"issue":"6","key":"10.1016\/j.intimp.2022.108791_b0695","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1128\/IAI.73.6.3814-3816.2005","article-title":"Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs","volume":"73","author":"Williams","year":"2005","journal-title":"Infect. Immun."},{"issue":"8","key":"10.1016\/j.intimp.2022.108791_b0700","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1128\/IAI.00287-09","article-title":"Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis","volume":"77","author":"Vordermeier","year":"2009","journal-title":"Infect. Immun."},{"issue":"5","key":"10.1016\/j.intimp.2022.108791_b0705","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1128\/CVI.00690-12","article-title":"Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques","volume":"20","author":"White","year":"2013","journal-title":"Clin. Vaccine Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2022.108791_b0710","doi-asserted-by":"crossref","first-page":"e23463","DOI":"10.1371\/journal.pone.0023463","article-title":"Th1\/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A","volume":"6","author":"Griffiths","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.intimp.2022.108791_b0715","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1164\/rccm.201108-1548OC","article-title":"A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and\/or Mycobacterium tuberculosis-infected adults","volume":"185","author":"Scriba","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b0720","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/eji.200939754","article-title":"Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells","volume":"40","author":"Scriba","year":"2010","journal-title":"Eur. J. Immunol."},{"issue":"9871","key":"10.1016\/j.intimp.2022.108791_b0725","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"The Lancet."},{"issue":"10","key":"10.1016\/j.intimp.2022.108791_b0730","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(14)70845-X","article-title":"Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial","volume":"14","author":"Satti","year":"2014","journal-title":"Lancet Infect. Dis."},{"issue":"10","key":"10.1016\/j.intimp.2022.108791_b0735","doi-asserted-by":"crossref","first-page":"6357","DOI":"10.4049\/jimmunol.173.10.6357","article-title":"Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis","volume":"173","author":"Wang","year":"2004","journal-title":"J. Immunol. (Baltimore, Md : 1950)"},{"issue":"8","key":"10.1016\/j.intimp.2022.108791_b0740","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1128\/IAI.00517-06","article-title":"Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis","volume":"74","author":"Santosuosso","year":"2006","journal-title":"Infect. Immun."},{"issue":"6","key":"10.1016\/j.intimp.2022.108791_b0745","doi-asserted-by":"crossref","first-page":"e5856","DOI":"10.1371\/journal.pone.0005856","article-title":"Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis","volume":"4","author":"Xing","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2022.108791_b0750","unstructured":"NCT00800670 CgI. Study of the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine, 2008. [http:\/\/clinicaltrialsgov\/ct2\/results?term=nct00800670&Search=Search]."},{"issue":"8","key":"10.1016\/j.intimp.2022.108791_b0755","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/mt.2009.130","article-title":"New insights on adenovirus as vaccine vectors","volume":"17","author":"Lasaro","year":"2009","journal-title":"Mol. Ther.: J. Am. Soc. Gene Therapy"},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b0760","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1172\/JCI60202","article-title":"Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine","volume":"122","author":"Frahm","year":"2012","journal-title":"J. Clin. Investig."},{"issue":"9653","key":"10.1016\/j.intimp.2022.108791_b0765","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"issue":"205","key":"10.1016\/j.intimp.2022.108791_b0770","doi-asserted-by":"crossref","first-page":"205ra134","DOI":"10.1126\/scitranslmed.3006843","article-title":"A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity","volume":"5","author":"Smaill","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"18","key":"10.1016\/j.intimp.2022.108791_b0775","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1016\/j.vaccine.2012.02.036","article-title":"Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis","volume":"30","author":"Brennan","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2022.108791_b0780","unstructured":"NCT02337270 CgI. Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine Administered by Aerosol, 2016. [https:\/\/clinicaltrialsgov\/ct2\/show\/NCT02337270]."},{"issue":"4","key":"10.1016\/j.intimp.2022.108791_b0785","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/trstmh\/trw016","article-title":"TB vaccine development and the End TB Strategy: importance and current status","volume":"110","author":"Fletcher","year":"2016","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2022.108791_b0790","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.tube.2016.05.008","article-title":"Epidemiologic studies and novel clinical research approaches that impact TB vaccine development","volume":"99","author":"Evans","year":"2016","journal-title":"Tuberculosis (Edinburgh, Scotland)."},{"key":"10.1016\/j.intimp.2022.108791_b0795","unstructured":"NCT02501421 CgI. Reactogenicity, Safety and Immunogenicity of a TB\/FLU-04L Tuberculosis Vaccine, 2015. [https:\/\/clinicaltrialsgov\/ct2\/show\/NCT02501421]."},{"issue":"7","key":"10.1016\/j.intimp.2022.108791_b0800","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1080\/21645515.2018.1458806","article-title":"The current status, challenges, and future developments of new tuberculosis vaccines","volume":"14","author":"Gong","year":"2018","journal-title":"Hum. Vaccines Immunotherap."},{"issue":"3","key":"10.1016\/j.intimp.2022.108791_b0805","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.intimp.2022.108791_b0810","unstructured":"NCT01829490 CgI. Safety Study of ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy Adults, 2013. [https:\/\/clinicaltrialsgov\/ct2\/show\/NCT01829490]."},{"issue":"48","key":"10.1016\/j.intimp.2022.108791_b0815","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1016\/j.vaccine.2015.10.017","article-title":"Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A","volume":"33","author":"Stylianou","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2022.108791_b0820","unstructured":"NCT03681860 CgI. EMaBS TB Vaccine Study. University of Oxford, 2018."},{"issue":"5","key":"10.1016\/j.intimp.2022.108791_b0825","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/infdis\/jiw228","article-title":"Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines","volume":"214","author":"Scriba","year":"2016","journal-title":"J. Infect. Dis."},{"issue":"3\u20134","key":"10.1016\/j.intimp.2022.108791_b0830","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tube.2006.01.024","article-title":"RUTI: a new chance to shorten the treatment of latent tuberculosis infection","volume":"86","author":"Cardona","year":"2006","journal-title":"Tuberculosis (Edinburgh, Scotland)."},{"issue":"5","key":"10.1016\/j.intimp.2022.108791_b0835","doi-asserted-by":"crossref","first-page":"e20404","DOI":"10.1371\/journal.pone.0020404","article-title":"Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis","volume":"6","author":"Vilaplana","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.intimp.2022.108791_b0840","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.vaccine.2009.09.134","article-title":"Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI","volume":"28","author":"Vilaplana","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b0845","doi-asserted-by":"crossref","first-page":"e89612","DOI":"10.1371\/journal.pone.0089612","article-title":"Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI: Randomized, Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection","volume":"9","author":"Nell","year":"2014","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.intimp.2022.108791_b0850","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.rmed.2005.09.026","article-title":"Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis","volume":"100","author":"Dlugovitzky","year":"2006","journal-title":"Respir. Med."},{"key":"10.1016\/j.intimp.2022.108791_b0855","unstructured":"S.O. Reber, P.H. Siebler, N.C. Donner, J.T. Morton, D.G. Smith, J.M. Kopelman, et al. Immunization with a heat-killed preparation of the environmental bacterium Mycobacterium vaccae promotes stress resilience in mice. 2016;113(22):E3130-9."},{"key":"10.1016\/j.intimp.2022.108791_b0860","unstructured":"L. Zhang, W. Ma, J. Da, [Mycobacterium vaccae influences the kinetics of Th1\/Th2 cells and expression of iNOS in a marine model of experimental tuberculosis]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin. J. Tuberculosis Respiratory Dis. 23(1) (2000) 43\u201346."},{"issue":"26","key":"10.1016\/j.intimp.2022.108791_b0865","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1016\/j.vaccine.2014.03.047","article-title":"Therapeutic vaccines for tuberculosis\u2013a systematic review","volume":"32","author":"Groschel","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2022.108791_b0870","doi-asserted-by":"crossref","unstructured":"Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Durban Immunotherapy Trial Group. Lancet. 354(9173) (1999) 116-119.","DOI":"10.1016\/S0140-6736(98)10448-8"},{"key":"10.1016\/j.intimp.2022.108791_b0875","doi-asserted-by":"crossref","unstructured":"R.E.P. Mayo, J.L. Stanford, Double-blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu, South Africa, 1991\u20131997. Trans. Roy. Soc. Trop. Med. Hygiene 94(5) (2000) 563-568.","DOI":"10.1016\/S0035-9203(00)90088-9"},{"issue":"9339","key":"10.1016\/j.intimp.2022.108791_b0880","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0140-6736(02)11141-X","article-title":"Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial","volume":"360","author":"Mwinga","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.intimp.2022.108791_b0885","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/QAD.0b013e3283350f1b","article-title":"Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine","volume":"24","author":"von Reyn","year":"2010","journal-title":"AIDS (London, England)."},{"issue":"10","key":"10.1016\/j.intimp.2022.108791_b0890","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2217\/imt.13.110","article-title":"Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7)","volume":"5","author":"Butov","year":"2013","journal-title":"Immunotherapy."},{"issue":"9","key":"10.1016\/j.intimp.2022.108791_b0895","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.4161\/hv.25280","article-title":"Randomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7)","volume":"9","author":"Efremenko","year":"2013","journal-title":"Hum. Vaccines Immunotherap."},{"key":"10.1016\/j.intimp.2022.108791_b0900","unstructured":"NCT01979900 Cgi. Phase III Clinical Study of Efficacy and Safety of Vaccae\u2122 to Prevent Tuberculosis, 2013. [https:\/\/clinicaltrialsgov\/ct2\/show\/NCT01979900]."},{"key":"10.1016\/j.intimp.2022.108791_b0905","unstructured":"NCT01979900 CgI. Phase III Clinical Study of Efficacy and Safety of Vaccae\u2122 to Prevent Tuberculosis. Anhui Zhifei Longcom Biologic Pharmacy Co, Ltd. 2013."},{"issue":"7","key":"10.1016\/j.intimp.2022.108791_b0910","doi-asserted-by":"crossref","first-page":"e6263","DOI":"10.1371\/journal.pone.0006263","article-title":"Polyphasic taxonomic analysis establishes Mycobacterium indicus pranii as a distinct species","volume":"4","author":"Saini","year":"2009","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b0915","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1038\/s41598-017-03514-1","article-title":"Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial","volume":"7","author":"Sharma","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2022.108791_b0920","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.tube.2016.10.002","article-title":"Mycobacterium indicus pranii as a booster vaccine enhances BCG induced immunity and confers higher protection in animal models of tuberculosis","volume":"101","author":"Saqib","year":"2016","journal-title":"Tuberculosis (Edinburgh, Scotland)."},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b0925","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/IAI.00526-08","article-title":"Immunogenicity and protective efficacy of \u201cMycobacterium w\u201d against Mycobacterium tuberculosis in mice immunized with live versus heat-killed M. w by the aerosol or parenteral route","volume":"77","author":"Gupta","year":"2009","journal-title":"Infect. Immun."},{"issue":"43","key":"10.1016\/j.intimp.2022.108791_b0930","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1016\/j.vaccine.2012.07.061","article-title":"Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in guinea pig model","volume":"30","author":"Gupta","year":"2012","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.intimp.2022.108791_b0935","doi-asserted-by":"crossref","first-page":"e0168521","DOI":"10.1371\/journal.pone.0168521","article-title":"Immunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis","volume":"11","author":"Lahey","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.intimp.2022.108791_b0940","unstructured":"NCT02712424 CgI. DAR-901 TB Booster Vaccine to Prevent TB in Adolescents (DAR-PIA), 2016. [https:\/\/clinicaltrialsgov\/ct2\/show\/NCT02712424]."},{"issue":"5","key":"10.1016\/j.intimp.2022.108791_b0945","doi-asserted-by":"crossref","first-page":"e0175215-e","DOI":"10.1371\/journal.pone.0175215","article-title":"Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901","volume":"12","author":"von Reyn","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.intimp.2022.108791_b0950","unstructured":"NCT02712424 CgI. DAR-901 TB Booster Vaccine to Prevent TB in Adolescents (DAR-PIA). Dartmouth-Hitchcock Medical Center, 2018."},{"issue":"34","key":"10.1016\/j.intimp.2022.108791_b0955","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1016\/j.vaccine.2009.05.050","article-title":"Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates","volume":"27","author":"Larsen","year":"2009","journal-title":"Vaccine."},{"issue":"11","key":"10.1016\/j.intimp.2022.108791_b0960","doi-asserted-by":"crossref","first-page":"e72786","DOI":"10.1371\/journal.pone.0072786","article-title":"A high-throughput screen against pantothenate synthetase (PanC) identifies 3-biphenyl-4-cyanopyrrole-2-carboxylic acids as a new class of inhibitor with activity against Mycobacterium tuberculosis","volume":"8","author":"Kumar","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.intimp.2022.108791_b0965","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1172\/JCI31947","article-title":"Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis","volume":"117","author":"Hinchey","year":"2007","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b0970","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2567.2006.02491.x","article-title":"Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine","volume":"120","author":"Derrick","year":"2007","journal-title":"Immunology"},{"issue":"37\u201339","key":"10.1016\/j.intimp.2022.108791_b0975","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1016\/j.vaccine.2006.05.097","article-title":"Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis","volume":"24","author":"Sambandamurthy","year":"2006","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.intimp.2022.108791_b0980","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/nm.2420","article-title":"A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis","volume":"17","author":"Sweeney","year":"2011","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.intimp.2022.108791_b0985","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.tips.2011.06.003","article-title":"Tuberculosis vaccines: progress and challenges","volume":"32","author":"Checkley","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2022.108791_b0990","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1128\/CVI.00015-11","article-title":"Relief from Zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens","volume":"18","author":"Johansen","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2022.108791_b0995","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00014-18","article-title":"Identification and Evaluation of Novel Protective Antigens for the Development of a Candidate Tuberculosis Subunit Vaccine","volume":"86","author":"Stylianou","year":"2018","journal-title":"Infect. Immun."},{"key":"10.1016\/j.intimp.2022.108791_b1000","unstructured":"intiative Tv. Pipeline of vaccines. TBVI. 2020."},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b1005","doi-asserted-by":"crossref","first-page":"8582","DOI":"10.1038\/s41598-017-09119-y","article-title":"Delta inulin-based adjuvants promote the generation of polyfunctional CD4(+) T cell responses and protection against Mycobacterium tuberculosis infection","volume":"7","author":"Counoupas","year":"2017","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.intimp.2022.108791_b1010","doi-asserted-by":"crossref","first-page":"e0143552","DOI":"10.1371\/journal.pone.0143552","article-title":"A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates","volume":"10","author":"Leung-Theung-Long","year":"2015","journal-title":"PLoS ONE"},{"issue":"13","key":"10.1016\/j.intimp.2022.108791_b1015","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.micinf.2009.07.005","article-title":"Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis","volume":"11","author":"Rouanet","year":"2009","journal-title":"Microbes Infect."},{"issue":"12","key":"10.1016\/j.intimp.2022.108791_b1020","doi-asserted-by":"crossref","first-page":"6799","DOI":"10.1128\/IAI.72.12.6799-6805.2004","article-title":"The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis","volume":"72","author":"Parra","year":"2004","journal-title":"Infect. Immun."},{"issue":"3\u20134","key":"10.1016\/j.intimp.2022.108791_b1025","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tube.2006.01.016","article-title":"Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis","volume":"86","author":"Locht","year":"2006","journal-title":"Tuberculosis (Edinburgh, Scotland)."},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b1030","doi-asserted-by":"crossref","first-page":"e31908","DOI":"10.1371\/journal.pone.0031908","article-title":"Protective and therapeutic efficacy of Mycobacterium smegmatis expressing HBHA-hIL12 fusion protein against Mycobacterium tuberculosis in mice","volume":"7","author":"Zhao","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.intimp.2022.108791_b1035","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1517\/14712598.2014.951630","article-title":"DNA vaccines against tuberculosis","volume":"14","author":"Bruffaerts","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b1040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.plasmid.2008.09.002","article-title":"A novel differential expression system for gene modulation in Mycobacteria","volume":"61","author":"Fan","year":"2009","journal-title":"Plasmid"},{"issue":"2\u20133","key":"10.1016\/j.intimp.2022.108791_b1045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0165-2478(03)00176-7","article-title":"Anti-mycobacterial immunity induced by a single injection of M. leprae Hsp65-encoding plasmid DNA in biodegradable microparticles","volume":"90","author":"Johansen","year":"2003","journal-title":"Immunol. Lett."},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b1050","first-page":"5","article-title":"The quest for a new vaccine against tuberculosis","volume":"3","author":"Delogu","year":"2009","journal-title":"J. Infect. Dev. Countries"},{"issue":"9","key":"10.1016\/j.intimp.2022.108791_b1055","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s11033-016-4024-9","article-title":"Construction and immunogenicity of a new Fc-based subunit vaccine candidate against Mycobacterium tuberculosis","volume":"43","author":"Kebriaei","year":"2016","journal-title":"Mol. Biol. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2022.108791_b1060","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1089\/dna.2014.2745","article-title":"Autophagy in the fight against tuberculosis","volume":"34","author":"Bento","year":"2015","journal-title":"DNA Cell Biol."},{"issue":"46","key":"10.1016\/j.intimp.2022.108791_b1065","doi-asserted-by":"crossref","first-page":"E3168","DOI":"10.1073\/pnas.1210500109","article-title":"Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation","volume":"109","author":"Castillo","year":"2012","journal-title":"PNAS"},{"issue":"6","key":"10.1016\/j.intimp.2022.108791_b1070","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.4049\/jimmunol.0803579","article-title":"ESAT-6 Inhibits Production of IFN-\u03b3 by Mycobacterium tuberculosis-Responsive Human T Cells","volume":"182","author":"Wang","year":"2009","journal-title":"J. Immunol. (Baltimore, Md : 1950)"},{"issue":"20","key":"10.1016\/j.intimp.2022.108791_b1075","doi-asserted-by":"crossref","first-page":"16930","DOI":"10.1074\/jbc.M111.327825","article-title":"Proline-Proline-Glutamic Acid (PPE) Protein Rv1168c of Mycobacterium tuberculosis Augments Transcription from HIV-1 Long Terminal Repeat Promoter","volume":"287","author":"Bhat","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"27","key":"10.1016\/j.intimp.2022.108791_b1080","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1016\/j.vaccine.2017.04.007","article-title":"\u201cThe Impact of Mycobacterium tuberculosis Immune Evasion on Protective Immunity: Implications for TB Vaccine Design\u201d \u2013 Meeting report","volume":"35","author":"Boggiano","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2022.108791_b1085","doi-asserted-by":"crossref","unstructured":"Sharebiani H, Hajimiri S, Abbasnia S, Soleimanpour S, Asnaashari H, Valizadeh N, et al. Game Theory Applications in Host-Microbe Interactions: <em>Mycobacterium tuberculosis<\/em> infection as an example. bioRxiv. 2020:2019.12.26.888602.","DOI":"10.1101\/2019.12.26.888602"},{"issue":"32","key":"10.1016\/j.intimp.2022.108791_b1090","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.1016\/j.vaccine.2010.05.063","article-title":"Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX protein","volume":"28","author":"Shi","year":"2010","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.intimp.2022.108791_b1095","doi-asserted-by":"crossref","first-page":"10587","DOI":"10.1007\/s00253-015-6962-x","article-title":"A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection","volume":"99","author":"Yuan","year":"2015","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2022.108791_b1100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.tube.2004.10.004","article-title":"A new vaccine against tuberculosis shows greater protection in a mouse model with progressive pulmonary tuberculosis","volume":"85","author":"Castanon-Arreola","year":"2005","journal-title":"Tuberculosis (Edinburgh, Scotland)."},{"issue":"6","key":"10.1016\/j.intimp.2022.108791_b1105","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.tube.2007.06.002","article-title":"Recombinant BCG Tokyo (Ag85A) protects cynomolgus monkeys (Macaca fascicularis) infected with H37Rv Mycobacterium tuberculosis","volume":"87","author":"Sugawara","year":"2007","journal-title":"Tuberculosis (Edinburgh, Scotland)."},{"issue":"12","key":"10.1016\/j.intimp.2022.108791_b1110","doi-asserted-by":"crossref","first-page":"e3869","DOI":"10.1371\/journal.pone.0003869","article-title":"Enhanced and Enduring Protection against Tuberculosis by Recombinant BCG-Ag85C and Its Association with Modulation of Cytokine Profile in Lung","volume":"3","author":"Ruchi Jain","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2022.108791_b1115","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fimmu.2014.00152","article-title":"Recombinant BCG: Innovations on an Old Vaccine. Scope of BCG Strains and Strategies to Improve Long-Lasting Memory","volume":"5","author":"da Costa","year":"2014","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108791_b1120","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1574-695X.2007.00322.x","article-title":"Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers effective protection against Mycobacterium tuberculosis in C57BL\/6 mice","volume":"51","author":"Xu","year":"2007","journal-title":"FEMS Immunol. Med. Microbiol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b1125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3390\/vaccines2010181","article-title":"Increasing the Vaccine Potential of Live M. bovis BCG by Coadministration with Plasmid DNA Encoding a Tuberculosis Prototype Antigen","volume":"2","author":"Bruffaerts","year":"2014","journal-title":"Vaccines (Basel)"},{"issue":"33","key":"10.1016\/j.intimp.2022.108791_b1130","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1016\/j.vaccine.2009.05.048","article-title":"Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis","volume":"27","author":"Sun","year":"2009","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.intimp.2022.108791_b1135","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1128\/IAI.00267-10","article-title":"Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice","volume":"78","author":"Sali","year":"2010","journal-title":"Infect. Immun."},{"key":"10.1016\/j.intimp.2022.108791_b1140","doi-asserted-by":"crossref","first-page":"17078","DOI":"10.1038\/srep17078","article-title":"Impact of Mycobacterium tuberculosis RD1-locus on human primary dendritic cell immune functions","volume":"5","author":"Etna","year":"2015","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.intimp.2022.108791_b1145","doi-asserted-by":"crossref","first-page":"5200","DOI":"10.1128\/IAI.00434-08","article-title":"A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG","volume":"76","author":"Tullius","year":"2008","journal-title":"Infect. Immun."},{"issue":"7","key":"10.1016\/j.intimp.2022.108791_b1150","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/abbs\/gmr045","article-title":"A novel recombinant Mycobacterium bovis bacillus Calmette-Guerin strain expressing human granulocyte macrophage colony-stimulating factor and Mycobacterium tuberculosis early secretory antigenic target 6 complex augments Th1 immunity","volume":"43","author":"Yang","year":"2011","journal-title":"Acta Biochim. Biophy. Sin."},{"issue":"7","key":"10.1016\/j.intimp.2022.108791_b1155","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/intimm\/dxf050","article-title":"IL-2-secreting recombinant bacillus Calmette Guerin can overcome a Type 2 immune response and corticosteroid-induced immunosuppression to elicit a Type 1 immune response","volume":"14","author":"Young","year":"2002","journal-title":"Int. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b1160","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1600-0463.2011.02815.x","article-title":"Recombinant BCG coexpressing Ag85B, CFP10, and interleukin-12 induces multifunctional Th1 and memory T cells in mice","volume":"120","author":"Lin","year":"2012","journal-title":"APMIS: acta pathologica, microbiologica, et immunologica Scandinavica."},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b1165","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2567.2006.02491.x","article-title":"Characterization of the protective T-cell response generated in CD4-de\u00accient mice by a live attenuated Mycobacterium tuberculosis vaccine","volume":"120","author":"Derrick","year":"2007","journal-title":"Immunology"},{"issue":"29\u201330","key":"10.1016\/j.intimp.2022.108791_b1170","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1016\/j.vaccine.2011.04.066","article-title":"Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate","volume":"29","author":"Sampson","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.intimp.2022.108791_b1175","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1128\/IAI.00023-10","article-title":"Immunogenicity and protection induced by a Mycobacterium tuberculosis sigE mutant in a BALB\/c mouse model of progressive pulmonary tuberculosis","volume":"78","author":"Hernandez Pando","year":"2010","journal-title":"Infect. Immun."},{"issue":"3","key":"10.1016\/j.intimp.2022.108791_b1180","doi-asserted-by":"crossref","first-page":"e01262","DOI":"10.1128\/mBio.01262-14","article-title":"Dietary pyridoxine controls efficacy of vitamin B6-auxotrophic tuberculosis vaccine bacillus Calmette-Guerin DeltaureC::hly Deltapdx1 in mice","volume":"5","author":"Gengenbacher","year":"2014","journal-title":"mBio"},{"issue":"6","key":"10.1016\/j.intimp.2022.108791_b1185","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1128\/IAI.00021-12","article-title":"Mycobacterium tuberculosis lacking all mycolic acid cyclopropanation is viable but highly attenuated and hyperinflammatory in mice","volume":"80","author":"Barkan","year":"2012","journal-title":"Infect. Immun."},{"issue":"5","key":"10.1016\/j.intimp.2022.108791_b1190","doi-asserted-by":"crossref","first-page":"e5531","DOI":"10.1371\/journal.pone.0005531","article-title":"Reducing the activity and secretion of microbial antioxidants enhances the immunogenicity of BCG","volume":"4","author":"Sadagopal","year":"2009","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b1195","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2172-14-S1-S5","article-title":"Mohd-Nor Norazmi. Immunogenicity of recombinant Mycobacterium bovis bacille Calmette-Gu\u00e8rin clones expressing T and B cell epitopes of Mycobacterium tuberculosis antigens","volume":"14","author":"Rohimah Mohamud","year":"2013","journal-title":"BMC Immunol."},{"issue":"3\u20134","key":"10.1016\/j.intimp.2022.108791_b1200","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.molimm.2012.11.014","article-title":"Mycobacterium tuberculosis antigen 85B and ESAT-6 expressed as a recombinant fusion protein in Mycobacterium smegmatis elicits cell-mediated immune response in a murine vaccination model","volume":"54","author":"Tsolaki","year":"2013","journal-title":"Mol. Immunol."},{"issue":"3\u20134","key":"10.1016\/j.intimp.2022.108791_b1205","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tube.2006.02.003","article-title":"Streptomyces as host for recombinant production of Mycobacterium tuberculosis proteins","volume":"86","author":"Vallin","year":"2006","journal-title":"Tuberculosis (Edinburgh, Scotland)"},{"key":"10.1016\/j.intimp.2022.108791_b1210","unstructured":"Partnership ST. TUBERCULOSIS VACCINE CANDIDATES \u2013 2011. Stop TB Partnership Working Group on New TB Vaccines, 2011."},{"issue":"4","key":"10.1016\/j.intimp.2022.108791_b1215","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/emmm.201000125","article-title":"Disruption of the SapM locus in Mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis","volume":"3","author":"Festjens","year":"2011","journal-title":"EMBO Mol Med."},{"issue":"44","key":"10.1016\/j.intimp.2022.108791_b1220","doi-asserted-by":"crossref","first-page":"7842","DOI":"10.1016\/j.vaccine.2011.07.094","article-title":"Protection of mice from Mycobacterium tuberculosis by ID87\/GLA-SE, a novel tuberculosis subunit vaccine candidate","volume":"29","author":"Windish","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.intimp.2022.108791_b1225","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/mi.2012.92","article-title":"Induction of protective immunity against Mycobacterium tuberculosis by delivery of ESX antigens into airway dendritic cells","volume":"6","author":"Dong","year":"2013","journal-title":"Mucosal Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2022.108791_b1230","doi-asserted-by":"crossref","first-page":"e72745","DOI":"10.1371\/journal.pone.0072745","article-title":"Subunit vaccine consisting of multi-stage antigens has high protective efficacy against Mycobacterium tuberculosis infection in mice","volume":"8","author":"Xin","year":"2013","journal-title":"PLoS ONE"},{"issue":"51","key":"10.1016\/j.intimp.2022.108791_b1235","doi-asserted-by":"crossref","first-page":"9451","DOI":"10.1016\/j.vaccine.2011.10.032","article-title":"Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX","volume":"29","author":"Niu","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.intimp.2022.108791_b1240","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.micinf.2010.11.002","article-title":"The immunity and protective effects of antigen 85A and heat-shock protein X against progressive tuberculosis","volume":"13","author":"Jeon","year":"2011","journal-title":"Microbes Infect."},{"issue":"23","key":"10.1016\/j.intimp.2022.108791_b1245","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1016\/j.vaccine.2009.03.018","article-title":"Intradermal immunization improves protective efficacy of a novel TB vaccine candidate","volume":"27","author":"Baldwin","year":"2009","journal-title":"Vaccine."},{"issue":"3","key":"10.1016\/j.intimp.2022.108791_b1250","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1073\/pnas.1314973111","article-title":"Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics","volume":"111","author":"Knudsen","year":"2014","journal-title":"PNAS"},{"issue":"3","key":"10.1016\/j.intimp.2022.108791_b1255","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nm.2104","article-title":"Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity","volume":"16","author":"Flatz","year":"2010","journal-title":"Nat. Med."},{"issue":"9871","key":"10.1016\/j.intimp.2022.108791_b1260","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"The Lancet."},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b1265","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/viro.2001.0864","article-title":"Recovery of Infectious Human Parainfluenza Type 2 Virus from cDNA Clones and Properties of the Defective Virus without V-Specific Cysteine-Rich Domain","volume":"284","author":"Kawano","year":"2001","journal-title":"Virology"},{"issue":"9","key":"10.1016\/j.intimp.2022.108791_b1270","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1128\/IAI.67.9.4780-4786.1999","article-title":"Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences","volume":"67","author":"Li","year":"1999","journal-title":"Infect. Immun."},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b1275","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.provac.2010.03.007","article-title":"A Novel Therapeutic and Prophylactic Vaccine (HVJ-Envelope \/ Hsp65 DNA + IL12 DNA) against Tuberculosis Using the Cynomolgus Monkey Model","volume":"2","author":"Okada","year":"2010","journal-title":"Proc. Vaccinol."},{"issue":"5","key":"10.1016\/j.intimp.2022.108791_b1280","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-3083.2010.02452.x","article-title":"DNA vaccine constructs expressing Mycobacterium tuberculosis-specific genes induce immune responses","volume":"72","author":"Hanif","year":"2010","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.intimp.2022.108791_b1285","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/srep01821","article-title":"Adjunctive immunotherapy with alpha-crystallin based DNA vaccination reduces Tuberculosis chemotherapy period in chronically infected mice","volume":"3","author":"Chauhan","year":"2013","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.intimp.2022.108791_b1290","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.nano.2012.02.015","article-title":"Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection","volume":"8","author":"Yu","year":"2012","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"14","key":"10.1016\/j.intimp.2022.108791_b1295","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.vaccine.2011.06.029","article-title":"Immunogenicity and protective efficacy of a tuberculosis DNA vaccine expressing a fusion protein of Ag85B-Esat6-HspX in mice","volume":"30","author":"Yuan","year":"2012","journal-title":"Vaccine."},{"issue":"1","key":"10.1016\/j.intimp.2022.108791_b1300","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.tube.2008.09.005","article-title":"Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene","volume":"89","author":"Changhong","year":"2009","journal-title":"Tuberculosis (Edinburgh, Scotland)."},{"issue":"4","key":"10.1016\/j.intimp.2022.108791_b1305","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.vaccine.2012.11.042","article-title":"Prime-boost BCG vaccination with DNA vaccines based in beta-defensin-2 and mycobacterial antigens ESAT6 or Ag85B improve protection in a tuberculosis experimental model","volume":"31","author":"Cervantes-Villagrana","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.intimp.2022.108791_b1310","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4161\/hv.27121","article-title":"A novel vaccine p846 encoding Rv3615c, Mtb10.4, and Rv2660c elicits robust immune response and alleviates lung injury induced by Mycobacterium infection","volume":"10","author":"Kong","year":"2014","journal-title":"Hum. Vaccines Immunotherap."},{"issue":"3","key":"10.1016\/j.intimp.2022.108791_b1315","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00430-011-0188-z","article-title":"A DNA vaccine expressing CFP21 and MPT64 fusion protein enhances BCG-induced protective immunity against Mycobacterium tuberculosis infection in mice","volume":"200","author":"Wang","year":"2011","journal-title":"Med. Microbiol. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2022.108791_b1320","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.vaccine.2006.09.088","article-title":"Oral vaccination of mice with lipid-encapsulated Mycobacterium bovis BCG: Effect of reducing or eliminating BCG load on cell-mediated immunity","volume":"25","author":"Cross","year":"2007","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.intimp.2022.108791_b1325","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1016\/j.celrep.2017.02.057","article-title":"Recombinant BCG expressing ESX-1 of Mycobacterium marinum combines low virulence with cytosolic immune signaling and improved TB protection","volume":"18","author":"Gr\u00f6schel","year":"2017","journal-title":"Cell Rep."},{"issue":"37","key":"10.1016\/j.intimp.2022.108791_b1330","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1016\/j.vaccine.2011.06.077","article-title":"Proteoliposomes from Mycobacterium smegmatis induce immune cross-reactivity against Mycobacterium tuberculosis antigens in mice","volume":"29","author":"Rodriguez","year":"2011","journal-title":"Vaccine"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922002752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922002752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:43:12Z","timestamp":1761586992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922002752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":266,"alternative-id":["S1567576922002752"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108791","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A century of attempts to develop an effective tuberculosis vaccine: Why they failed?","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108791","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108791"}}